Search Results

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are still chasing these multi-billion-dollar markets.

MilliporeSigma and The Michael J. Fox Foundation for Parkinson’s Research (MJFF), are advancing research aimed at slowing progression of Parkinson’s disease (PD).

Kannalife Sciences, Inc. is pleased to announce it has been awarded funding of $1,493,409 million from The Michael J. Fox Foundation for Parkinson’s Research.

Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression.

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.

Spur Therapeutics, formerly Freeline Therapeutics, today announced new data from its GBA1 Parkinson’s disease research program demonstrating that its rationally engineered GCase85 enzyme reduces the accumulation of α-Synuclein, a protein that plays a significant role in the development and progression of Parkinson’s disease, more effectively than wildtype glucocerebrosidase (GCase) in in vitro studies.

The Michael J. Fox Foundation for Parkinson’s Research announced $9.75 million in total awards to five research teams working on tools to biologically measure and track the progression of Parkinson’s disease from its earliest detection through more advanced stages.

CLINUVEL announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.